EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 316 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New Treatment Helps Survivors Regain Sensation After Breast Cancer October 21, 2020 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 Reunión anual de la American Society of Clinical Oncology de 2021:... June 3, 2021 Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers September 27, 2023 Load more HOT NEWS Worried Cancer Patients Face Delayed Treatment Because Of Pandemic Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A Can a Biopsy Make My Cancer Spread? ESMO Welcomes the WHO Global Status Report on Cancer with Key...
